Catalyst Biosciences Inc (NASDAQ:CBIO) was the target of unusually large options trading on Tuesday. Stock investors bought 835 call options on the company. This represents an increase of approximately 1,418% compared to the typical volume of 55 call options.
Shares of Catalyst Biosciences (CBIO) opened at $29.43 on Wednesday. Catalyst Biosciences has a 1 year low of $3.11 and a 1 year high of $37.00.
A number of analysts have commented on CBIO shares. Zacks Investment Research upgraded Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Wednesday, November 8th. B. Riley started coverage on Catalyst Biosciences in a research report on Friday, December 8th. They issued a “buy” rating and a $19.00 price target for the company. ValuEngine upgraded Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, Chardan Capital upped their price target on Catalyst Biosciences from $10.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $37.50.
Large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP grew its position in shares of Catalyst Biosciences by 117.0% during the third quarter. Dimensional Fund Advisors LP now owns 173,555 shares of the biopharmaceutical company’s stock worth $873,000 after purchasing an additional 93,592 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Catalyst Biosciences during the second quarter worth about $107,000. Vanguard Group Inc. grew its position in shares of Catalyst Biosciences by 294.1% during the second quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 32,621 shares in the last quarter. Geode Capital Management LLC purchased a new stake in shares of Catalyst Biosciences during the fourth quarter worth about $379,000. Finally, Raymond James & Associates purchased a new stake in shares of Catalyst Biosciences during the fourth quarter worth about $585,000. Hedge funds and other institutional investors own 29.64% of the company’s stock.
About Catalyst Biosciences
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.